A simplified absorption-type split will be implemented to transfer the GMP cell processing contract manufacturing business to S-RACMO, effective January 1, 2027. Takara Bio will concentrate on CDMO areas and optimize its business portfolio, improving efficiency of management resources through asset sales and workforce reductions. The impact on consolidated results is expected to be minor.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2531","jir_company_name":"Takara Holdings Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-02","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/2531-20261102-01.pdf","jir_short_summary":"A simplified absorption-type split will be implemented to transfer the GMP cell processing contract manufacturing business to S-RACMO, effective January 1, 2027. Takara Bio will concentrate on CDMO areas and optimize its business portfolio, improving efficiency of management resources through asset sales and workforce reductions. The impact on consolidated results is expected to be minor.","jir_summary":"### Overview of the Transaction\nTakara Holdings Inc. resolved to transfer the GMP cell processing contract manufacturing business of consolidated subsidiary Takara Bio Inc. to S-RACMO by an absorption-type split. The effective date is scheduled to be January 1, 2027, and the split method will be a simplified absorption-type split. In conjunction with the succession, Takara Bio will focus resources on core modalities such as nucleic acids\/plasmids, proteins\/enzymes, and viral vectors. The company will improve the efficiency of management resources through workforce reductions while securing employment opportunities, obtaining consideration for the transfer, and selling equipment.\n\n### Outlook and Impact\nThere will be no changes to Takara Bio's name, location, business description, capital, or fiscal year-end after the absorption-type split, and the impact on the Company's consolidated results is expected to be minor. Rights and obligations to be succeeded will transfer as stipulated in the absorption-type split agreement. S-RACMO is scheduled to obtain shareholder meeting approval before the day preceding the absorption-type split.","jir_financial_highlights":"Capital: Unknown (Unknown)\nNet sales: Unknown (Unknown)\nNet income attributable to owners of parent: Unknown (Unknown)","jir_category":"","jir_hashtags":"#TakaraHoldings, #ShareBuyback, #ExecutivePersonnel","jir_key_figures":"Absorption-type split schedule: 2026-11-02 Signing date of the basic agreement, 2026-11-16 Signing date of the absorption-type split agreement (scheduled), 2027-01-01 Effective date (scheduled)\nBusiness to be succeeded: GMP cell processing contract manufacturing business (CDMO area)\nAffiliated companies: Takara Bio Inc., S-RACMO Inc.","jir_meta_title":"Takara Holdings Inc. Announces Simplified Absorption-Type Split to Transfer GMP Cell Processing Contract Manufacturing Business\uff5cNovember 2026","jir_meta_description":"Takara Holdings Inc. announced an absorption-type split to transfer Takara Bio Inc.'s GMP cell processing contract manufacturing business to S-RACMO, promoting portfolio optimization and more efficient allocation of management resources. The effective date is scheduled for January 1, 2027.","jir_og_title":"Takara Holdings Inc.\uff5cSimplified Absorption-Type Split to Transfer GMP Cell Processing Contract Manufacturing Business","jir_og_description":"Takara Holdings Inc. announced a simplified absorption-type split to transfer Takara Bio Inc.'s GMP cell processing contract manufacturing business to S-RACMO. The impact is expected to be minor while promoting resource efficiency.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":8130,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"corporate_restructuring","footnotes":""},"sector":[],"importance":[],"class_list":["post-139535","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n